B-Cell-Targeted 3DNA Nanotherapy Against Indoleamine 2,3-Dioxygenase 2 (IDO2) Ameliorates Autoimmune Arthritis in a Preclinical Model
Open Access
- 1 January 2020
- journal article
- research article
- Published by SAGE Publications in Clinical Pathology
- Vol. 13
Abstract
The tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase 2 (IDO2) has been identified as an immunomodulatory agent promoting autoimmunity in preclinical models. As such, finding ways to target the expression of IDO2 in B cells promises a new avenue for therapy for debilitating autoimmune disorders such as rheumatoid arthritis. IDO2, like many drivers of disease, is an intracellular protein expressed in a range of cells, and thus therapeutic inhibition of IDO2 requires a mechanism for targeting this intracellular protein in specific cell types. DNA nanostructures are a promising novel way of delivering small molecule drugs, antibodies, or siRNAs to the cytoplasm of a cell. These soluble, branched structures can carry cell-specific targeting moieties along with their therapeutic deliverable. Here, we examined a 3DNA nanocarrier specifically targeted to B cells with an anti-CD19 antibody. We find that this 3DNA is successfully delivered to and internalized in B cells. To test whether these nanostructures can deliver an efficacious therapeutic dose to alter autoimmune responses, a modified anti-IDO2 siRNA was attached to B-cell-directed 3DNA nanocarriers and tested in an established preclinical model of autoimmune arthritis, KRN.g7. The anti-IDO2 3DNA formulation ameliorates arthritis in this system, delaying the onset of joint swelling and reducing total arthritis severity. As such, a 3DNA nanocarrier system shows promise for delivery of targeted, specific, low-dose therapy for autoimmune disease.Keywords
This publication has 43 references indexed in Scilit:
- Targeting CD19 in B-cell lymphoma: emerging role of SAR3419Cancer Management and Research, 2013
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care & Research, 2012
- Treating Human Autoimmunity: Current Practice and Future ProspectsScience Translational Medicine, 2012
- Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenaseProceedings of the National Academy of Sciences, 2012
- Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of CareClinical Therapeutics, 2011
- Societal cost of rheumatoid arthritis patients in the USCurrent Medical Research and Opinion, 2009
- Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammationProceedings of the National Academy of Sciences, 2008
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IArthritis & Rheumatism, 2007
- Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in miceArthritis Research & Therapy, 2007
- Therapeutic strategies for rheumatoid arthritisNature Reviews Drug Discovery, 2003